Use of prostaglandin A1 in treatment of nerve degenerative diseases such as cerebral ischemia apoplexy

A technology of prostaglandins and cerebral ischemia, applied in cardiovascular system diseases, drug combinations, nervous system diseases, etc., to reduce neuron damage, inhibit inflammatory response, and have low toxicity effects

Inactive Publication Date: 2005-08-17
秦正红 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are many studies on the anti-inflammatory, anti-viral and anti-tumor effects of prostaglandin A series, but these studies have not been applied clinically

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0012] Example: Prostaglandin A1 was tried in the treatment of essential hypertension, renal hypertension and acute renal failure in the 1970s. According to the animal experiment results of prostaglandin A1 treatment of ischemic stroke, and the fact that prostaglandin A1 can be made into microliposome preparations, the present invention can use prostaglandin A1 microliposome preparations in the treatment of ischemic stroke and other neurodegenerative diseases. Liposome intravenous infusion. The intended dose is 1 μg / min, which is added to normal saline and instilled at a constant rate.

[0013] The basic researches supporting the protective effect of prostaglandin A1 on nerve cells include:

[0014] 1. Prostaglandin A1 can effectively resist nerve cell damage caused by toxins caused by excitatory amino acids.

[0015] Excitatory amino acid receptors play an important role in maintaining normal brain function, but excessive activation of these receptors can lead to nerve cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The prostaglandin A1 is an endogenous active substance obtained by means of conversion of cell membrane lipid in vivo, it can obviously reduce neuronal injury due to ischemia, in the animal experiment is can reduce cerebral infarction area by above 40%, in particular, the administration after ischemia is still effective, it can not be obtained by general medicine in treating apoplexy. Said prostaglandin A1 is small in toxicity, safe, and has a certain therapeutic effect in creating other nervous retrograde diseases, such as Parkinson's disease, Huntington's chorea and senile dementia, etc.

Description

technical field [0001] The invention relates to a new application of prostaglandin A1. Background technique [0002] Prostaglandins are biologically active substances with various physiological effects and composed of a class of unsaturated fatty acids that exist in the body including the central nervous system. The chemical nature of prostaglandins is composed of a five-membered ring and two 20-carbon unsaturated fatty acid side chains. Prostaglandins are converted from lipids on cell membranes by enzymatic methods. There are multiple series of prostaglandins in the body, including A, B, C, D, E, F, G, H, I and other types. Various prostaglandins have different biochemical properties and biological effects. Prostaglandins have effects on the endocrine, reproductive, digestive, cardiovascular, urinary and nervous systems. Among them, prostaglandin E1 and prostaglandin I2 have more researches on cardiovascular aspects and have been applied clinically. Prostaglandin Fα2 has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/5575A61P9/10A61P25/14A61P25/16A61P25/28
Inventor 秦正红顾振纶
Owner 秦正红
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap